Significant Ownership of Unleash Immuno Oncolytics, Inc.
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Unleash Immuno Oncolytics, Inc. focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/Daniel Eduardo Katzman - Daniel Eduardo Katzman/Chief Executive Officer
- Manager location
- St. Louis, MO
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Unleash Immuno Oncolytics, Inc. with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Unleash Immuno Oncolytics, Inc.
Significant Ownership of Unleash Immuno Oncolytics, Inc.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| RNAZ | TransCode Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 9.9% | $1,875,000 | 300,000 | Unleash Immuno Oncolytics, Inc. | 23 Jul 2026 |
Schedules 13D/G Reported by Unleash Immuno Oncolytics, Inc.:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.